Neuropathic Pain Market Report 2026

Neuropathic Pain Market Overview

• Neuropathic Pain market size has reached to $5.78 billion in 2025 • Expected to grow to $8.48 billion in 2030 at a compound annual growth rate (CAGR) of 8.1% • Growth Driver: Rising Prevalence Of Chronic Pain Drives Growth In The Neuropathic Pain Market • Market Trend: Integration Of Artificial Intelligence Revolutionizes Neuropathic Pain Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neuropathic Pain Market?

Neuropathic pain is chronic pain caused by damage or dysfunction in the nervous system and characterized by burning, tingling, shooting, or electric shock-like sensations. Neuropathic pain can be challenging to treat and may be caused by nerve injuries, diabetes, multiple sclerosis, nerve compression, neural degeneration and central nervous system disorders. The main types of neuropathic pain treatment are medications and multimodal therapy. Medications involve the use of pharmaceutical substances to alleviate symptoms or manage conditions and certain medications, such as anticonvulsants, antidepressants and opioids, can target nerve-related abnormalities and pathways, reducing the intensity of neuropathic pain signals and providing relief. Neuropathic pain is diagnosed by imaging, blood tests and physical examination procedures indicated for diabetic neuropathy, spinal stenosis, chemotherapy-induced peripheral neuropathy and others provided by hospitals, clinics, home healthcare, ambulatory surgical centers and others.

What Is The Neuropathic Pain Market Growth Forecast?

The neuropathic pain market size is expected to see strong growth in the next few years. It will grow to $8.48 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to growing shift toward non-opioid therapies, rising demand for personalized pain management, expansion of complementary therapy usage, increasing investment in diagnostic innovations, development of advanced multimodal treatment solutions. Major trends in the forecast period include rising adoption of multimodal therapy approaches, increasing demand for non-opioid pain management, growing use of physical and psychological therapy integration, expansion of early diagnosis through imaging techniques, increasing focus on diabetic neuropathy treatment.

Global Neuropathic Pain Market Segmentation

1) By Treatment: Medications, Multimodal Therapy 2) By Diagnosis: Imaging, Blood Tests And Physical Examination 3) By Indication: Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Other Indications 4) By End User: Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Other End Users Subsegments: 1) By Medications: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 2) By Multimodal Therapy: Combination Of Medications, Physical Therapy, Psychological Therapy, Lifestyle Modifications, Complementary Therapies

What Is The Driver Of The Neuropathic Pain Market?

The rising prevalence of chronic pain is expected to propel the growth of the neuropathic pain market going forward. Chronic pain is defined as persistent discomfort lasting three months or more it affects a substantial portion of the population and significantly impacts quality of life. The increase in chronic pain cases is driven by factors such as aging populations, nerve damage, and chronic illnesses like diabetes. Neuropathic pain therapies support public health by targeting nerve dysfunction, relieving symptoms, and improving patients’ daily functioning. For instance, in November 2024, according to the data published by the Centers for Disease Control and Prevention (CDC), a US-based nation's health protection agency, adult populations experienced 24.3% prevalence of chronic pain and 8.5% prevalence of high-impact chronic pain in 2023 equivalent to 34.9% among those with chronic pain with women, American Indian and Alaska Native adults, and individuals aged 65 years and older showing notably higher rates. Therefore, the rising prevalence of chronic pain is driving the neuropathic pain industry.

Key Players In The Global Neuropathic Pain Market

Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol‑Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc, Medtronic Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., Nevro Corp., InvaGen Pharmaceuticals Inc, Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Assertio Therapeutics Inc, NeuroMetrix Inc, OMRON Healthcare Co Ltd

Global Neuropathic Pain Market Trends and Insights

Major companies operating in the neuropathic pain market are adopting artificial intelligence technologies for advanced diagnosis, tailored treatment plans, real-time monitoring, drug discovery and data-driven insights to enhance patient outcomes and refine pain management strategies. For instance, in March 2023, Nevro Corp., a US-based medical device company, launched the Senza HFX iQ spinal cord stimulation (SCS) system. This innovative technology employs artificial intelligence (AI) to customize pain relief for individual patients. The system, which includes the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger and HFX App, is designed to treat non-surgical back pain and painful diabetic neuropathy by adapting to patient responses and feedback. It uses a unique algorithm based on extensive patient data and allows patients to adjust their pain relief program via a smartphone app. The system's digital environment enables data collection and potential updates. The technology aims to enhance pain relief through consistency and personalization, marking a significant advance in SCS therapy.

What Are Latest Mergers And Acquisitions In The Neuropathic Pain Market?

In July 2023, Novartis AG, a Switzerland-based multinational pharmaceutical corporation focused on innovative medicines, acquired DTx Pharma for an undisclosed amount. This acquisition allows Novartis to utilize DTx's expertise in small interfering ribonucleic acid (siRNA) therapies for neurological disorders, enhancing its capacity to meet unmet medical needs and expediting the introduction of innovative treatments for patients. DTx Pharma is a US-based preclinical biotechnology company that develops RNA-based therapies for neuropathic pain.

Regional Outlook

North America was the largest region in the neuropathic pain market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neuropathic Pain Market?

The neuropathic pain market consists of revenues earned by entities by providing physical therapy services, acupuncture services and relaxation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuropathic pain market also includes sales of anticonvulsants, antidepressants, opioids, topical creams and transcutaneous electrical nerve stimulation devices, which are used in providing neuropathic pain diagnosis and treatment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neuropathic Pain Market Report 2026?

The neuropathic pain market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neuropathic pain industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.